Gamida Cell Ltd. is a world leader in stem cell expansion technologies
and products and will potentially be the first to bring an allogeneic
cell therapy to the market. The company is developing a diversified
pipeline of cell products intended to effectively treat debilitating
and often fatal illnesses such as cancer, cardiovascular disease,
peripheral vascular disease and neurological disorders. Gamida Cell’s
therapeutic candidates contain adult stem cells, selected from noncontroversial
sources (usually umbilical cord blood), and which are
enriched in culture using the company’s proprietary technologies. The
company’s enabling technologies have been developed into robust
Gamida Cell’s flagship product, StemEx, is being developed by the
Gamida Cell - Teva Joint Venture. StemEx is poised to answer a
dire unmet clinical need in the field of bone marrow transplantation.
StemEx is currently being studied as a treatment for leukemia and
lymphoma in a global, multi-center, FDA/European regulatory guided,
pivotal registration study called ExCell, which is now enrolling at
prestigious clinical sites in the U.S., Europe and Israel. Gamida Cell
anticipates that StemEx will be on the market by 2010.
In 2008, the company will begin Phase I/II clinical studies on
CardioCure, a product for cardiac regeneration in patients who have
suffered a heart attack. In 2009, Gamida Cell plans to commence
Phase I/II studies on a product to treat Peripheral Vascular Disease.
Shareholders include: Elbit Imaging, Biomedical Investment, Israel
Healthcare Venture, Teva Pharmaceuticals, Denali Ventures and